CONTINuous Infra-Inguinal Stenting Using the Bard® LifeStent® VascUlar Stent SysteMs ("CONTINUUM")

NCT ID: NCT00908947

Last Updated: 2019-11-19

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: NA
• Total Enrollment: 173 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2011-02-28
• Study Completion Date: 2018-09-19

Brief Summary

The objectives of this study are to collect post-market confirmatory evidence of the safety and effectiveness of the Bard® LifeStent® Vascular Stent System and LifeStent® XL Vascular Stent System (together the "LifeStent® Vascular Stent System").

Detailed Description

The study is a prospective, multi-center, single-arm, non-randomized study enrolling up to 234 subjects with lifestyle-limiting claudication or ischemic rest pain attributable to lesion(s) (stenosed, occluded, restenosed, or re-occluded) in the infra-inguinal segment (Superficial femoral artery [SFA] and/or proximal popliteal artery) that are amenable to treatment by percutaneous transluminal angioplasty (PTA) and stenting. All subjects enrolled in the study will receive PTA and stenting.

Conditions

Superficial Femoral Artery Stenosis

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Overall Study

PTA plus stenting with the LifeStent® Vascular Stent System

Group Type: EXPERIMENTAL

PTA followed by placement of LifeStent® Vascular Stent

Intervention Type: DEVICE

PTA followed by placement of LifeStent® Vascular Stent

Interventions

PTA followed by placement of LifeStent® Vascular Stent

PTA followed by placement of LifeStent® Vascular Stent

Intervention Type: DEVICE

Other Intervention Names

LifeStent® Vascular Stent; LifeStent® XL Vascular Stent; LifeStent® SOLO(TM) Vascular Stent

Eligibility Criteria

Inclusion Criteria

1. The subject provides written informed consent using an Informed Consent Form (ICF) that is reviewed and approved by the Institutional Review Board (IRB) for the site.

2. Subject agrees to comply with the protocol-mandated follow-up procedures and visits.

3. The subject is ≥ 21 years old.

4. Male or female subjects; female subjects of childbearing potential must have a negative urine pregnancy test at the time of screening.

5. The subject has lifestyle-limiting claudication or ischemic rest pain defined as: Rutherford Category 2-4.

6. The target lesion(s) has angiographic evidence of stenosis or restenosis ≥ 50% or occlusion (by visual estimate) and is amenable to PTA with stenting.

7. The total target lesion(s) length must be ≤ 240 mm.

8. The target vessel reference diameter is ≥ 4.0 mm and ≤ 6.5 mm (by visual estimate), and therefore appropriate for treatment with available stent diameters of 6.0 mm and 7.0 mm.

Exclusion Criteria

1. The subject is unable or unwilling to provide informed consent, or is unable or unwilling to conform to the study protocol follow-up procedures and visits.

2. The subject has claudication or critical limb ischemia described as Rutherford Category 1 (mild claudication), 5 (minor tissue loss) or 6 (major tissue loss.

3. The subject has multiple stenoses or occlusions > 240 mm.

4. The subject has a previous stent or stent graft located in the target vessel.

5. The subject has flow-limiting stenosis or occlusion of the inflow tract that cannot be adequately corrected (≤ 30% residual stenosis) prior to treatment of the target lesion(s). Investigator standard of care practices shall be utilized for treatment of inflow.

6. The subject has a known contraindication (including allergic reaction) to antiplatelet/anticoagulant medications, nickel, titanium, tantalum or sensitivity.

7. The subject has a known contraindication to contrast media that is not amenable to pretreatment with steroids or/and antihistamines.

8. The subject has a known history of bleeding diatheses or coagulopathy.

9. The subject has concomitant renal failure with a creatinine of > 2.5 mg/dL.

10. The subject is currently on dialysis or receiving systemic immunosuppressive therapy.

11. The subject has known concomitant hepatic insufficiency, thrombophlebitis, uremia, systemic lupus erythematosus, septicemia or deep vein thrombosis at the time of the index procedure.

12. The subject is currently participating in an investigational drug or another investigational device study that has not completed the primary endpoint, or that clinically interferes with the study endpoints. Note: trials requiring extended follow-up for products that were investigational, but have since become commercially available, are not considered investigational trials.

13. The subject has another medical condition, which, in the opinion of the Investigator, may cause him/her to be non-compliant with the protocol, confound the data interpretation, or is associated with a life expectancy insufficient to allow for the completion of study procedures and follow-up.

14. The subject has extensive peripheral vascular disease, which in the opinion of the Investigator, would preclude safe insertion of an introducer sheath.

15. The target lesion(s) is located within an aneurysm or associated with an aneurysm in the vessel segment either proximal or distal to the target lesion(s).

16. There is angiographic evidence of unresolved thrombus at the target lesion(s) or within the target vessel that does not resolve with infusion of thrombolytics and/or mechanical thrombectomy (using an approved device) without adverse events/complications.

17. The subject has undergone any non-iliac percutaneous intervention(s) < 7 days prior to the index procedure.

• Minimum Eligible Age: 21 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

C. R. Bard

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Jeffrey P Carpenter, MD

Role: PRINCIPAL_INVESTIGATOR

The Cooper Health System

Mark D Mewissen, MD

Role: PRINCIPAL_INVESTIGATOR

Wake Forest University Health Sciences

Locations

VA Greater Los Angeles Healthcare System

Los Angeles, California, United States

Mission Cardiovascular Research Institute

Pleasanton, California, United States

South Florida Medical Imaging, PA

Fort Lauderdale, Florida, United States

Baptist Hospital of Miami

Miami, Florida, United States

Mount Sinai Medical Center

Miami Beach, Florida, United States

Loyola University Chicago

Chicago, Illinois, United States

Heartland Vascular Center

Joliet, Illinois, United States

Prairie Education and Research Cooperative (PERC)

Springfield, Illinois, United States

Cardiovascular Research of Northwest Indiana, LLC.

Munster, Indiana, United States

University of Kansas Medical Center Research Institute, Inc.

Kansas City, Kansas, United States

Kentucky Heart Foundation

Ashland, Kentucky, United States

Steward St. Elizabeth Medical Center of Boston Inc.

Boston, Massachusetts, United States

Metropolitan Hospital d/b/a Metro Health Hospital

Wyoming, Michigan, United States

Midwest Aortic Vascular Institute P.C

North Kansas City, Missouri, United States

The Cooper Health System

Camden, New Jersey, United States

Saint Peter's University Hospital

New Brunswick, New Jersey, United States

The Huntington Heart Center

Huntington, New York, United States

Saint Vincent Consultants in Cardiovascular Diseases, LLC

Erie, Pennsylvania, United States

Trustees of the University of Pennsylvania

Philadelphia, Pennsylvania, United States

Allegheny-Singer Research Institute

Pittsburgh, Pennsylvania, United States

PinnacleHealth Cardiovascular Institute

Wormleysburg, Pennsylvania, United States

South Carolina Heart Center, P.A.

Columbia, South Carolina, United States

McLeod Regional Medical Center

Florence, South Carolina, United States

Sanford Research

Sioux Falls, South Dakota, United States

University Surgical Associates, LLC

Chattanooga, Tennessee, United States

BCS Heart, LLP.

College Station, Texas, United States

Houston Center for Vascular Health

Houston, Texas, United States

The Methodist Hospital Research Institute dba Houston Methodist Research Institute

Houston, Texas, United States

Aurora Medical Group

Milwaukee, Wisconsin, United States

Countries

United States

Provided Documents

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

BPV-08-001

Identifier Type: -

Identifier Source: org_study_id